Skip to search formSkip to main contentSkip to account menu

LY 2189265

Known as: LY-2189265, LY2189265 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dulaglutide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
Purpose For patients with type 2 diabetes (T2DM) who remain above their glycemic target on insulin therapy, a combination of… 
Review
2017
Review
2017
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
For the purpose of exploring the development, pharmacology and clinical trial program related to dulaglutide, we conducted a… 
2016
2016
Drug Profile Dulaglutide ( LY-2189265 ) for the treatment of type 2 diabetes
Dulaglutide is a,new once-weekly glucagon-like peptide-1 receptor agonist for the management of hyperglycemia in adult patients… 
2014
2014
In metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels
Question In patients with uncontrolled type 2 diabetes who are receiving metformin therapy, is weekly dulaglutide noninferior to… 
2014
2014
PO35 Analyse post-hoc des données poolées de deux essais de phase III contrôlés contre placebo AWARD-1 et AWARD-5 (Assessment of weekly administration of LY2189265 in Diabetes – 1 and – 5/ Évaluation…
2014
2014
A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide…
2009
2009
a novel adaptive dose-finding study to develop LY2189265, a once-weekly GLP-1 analog
2009
2009
Effect of LY2189265, a long-acting glucagon-like peptide 1 analog, on metabolic outcomes and GI events in obese patients with uncontrolled type 2 diabetes mellitus (T2DM): The EGo study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)